Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on R 3 Hydroxybutyric Acid. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN107162893A details Ru-catalyzed asymmetric hydrogenation for high-purity (R)-3-HB. Offers cost reduction in pharma manufacturing and scalable supply chain solutions.
Patent CN101392225A reveals a recombinant yeast route for high-purity (S)-CHBE, offering significant cost reduction in API manufacturing and robust supply chain scalability.
Novel ketoreductase mutant enables high-purity pharmaceutical intermediates manufacturing with substantial cost reduction and enhanced supply chain reliability for global partners.
Patent CN114908129B reveals a novel dehydrogenase mutant for high-purity (R)-4-chloro-3-hydroxybutyric acid ethyl ester production, offering significant cost and supply chain advantages.
Patent CN105543186A reveals novel biocatalytic route for high-purity chiral alcohols. Enables cost reduction in chiral alcohol manufacturing and supply chain reliability.
Patent CN109852593B details a high-activity CmCR mutant for R-3HB production, offering significant cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN112680425B reveals a novel alcohol dehydrogenase mutant for producing high-purity (S)-CHBE. This biocatalytic route offers significant cost reduction and supply chain reliability for statin manufacturing.
Patent CN104651292A reveals high-purity S-CHBE synthesis via recombinant E. coli. Achieves 100% conversion and 99.4% ee for scalable pharmaceutical intermediates.
Patent CN113652408A reveals a novel carbonyl reductase mutant for efficient (R)-4-chloro-3-hydroxybutyric acid ethyl ester production, offering superior yield and green manufacturing advantages.